Drug Profile
Mazdutide - Eli Lilly and Company
Alternative Names: IBI-362; LY-3305677; OXM-3Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Innovent Biologics
- Class Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides; Uricosurics
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Obesity
- Phase III Type 2 diabetes mellitus
- Preclinical Hyperuricaemia